BioNxt Solutions Advances Drug Delivery Platform with New Technology Agreement

Bionxt Solutions CA0909741062

BioNxt Solutions is taking strategic action to enhance its melt-in-the-mouth film technology. The company announced a move to secure exclusive access to a complementary drug delivery system, signaling an expansion of its pharmaceutical platform capabilities. This development comes at a pivotal moment, following recent positive research data from the company's own pipeline.

On February 5, 2026, BioNxt confirmed it has signed a non-binding Letter of Intent (LOI). The agreement outlines plans to obtain exclusive rights to an advanced chaperone technology designed for orally soluble applications.

The core objective is to tackle common challenges in drug formulation, specifically focusing on improving a medication's stability and the efficiency of its absorption into the body. BioNxt intends to integrate this technology with its existing ODF (orally dissolving film) platform. This synergy is expected to be particularly valuable for sublingual (under the tongue) and buccal (inside the cheek) products, where reliable and consistent drug delivery is paramount.

The company has identified a clear application pathway. The focus will be on reformulating already approved drug substances into fast-dissolving, swallow-free dosage forms. This approach could prove highly relevant for treating neurological and chronic diseases, where patient adherence to therapy and precise dosing are frequent obstacles.

Context and Timing: Building on Recent Preclinical Success

This strategic announcement follows closely on the heels of operational progress reported by BioNxt in January. The company released final results from a preclinical study on January 21, 2026, comparing its proprietary Cladribine ODF formulation to conventional tablets for potential use in multiple sclerosis.

The data revealed that the sublingual ODF version achieved approximately 40% higher bioavailability in animal models than traditional oral tablets. BioNxt has stated that these results provide the scientific foundation for advancing into human pharmacokinetic studies.

The newly proposed chaperone technology is seen as a potential tool to further refine this delivery mechanism. By potentially enhancing the drug's properties, it could strengthen BioNxt's position in the growing market for innovative oral dosage forms.

Key Considerations for the Market

Investors are likely monitoring two parallel tracks of development following this news:

• Finalizing the Deal: The market will watch for the conversion of the non-binding LOI into a definitive agreement. Subsequent technical integration of the new technology into BioNxt's platform will be a critical measure of success.
• Clinical Pipeline Momentum: The speed at which the Cladribine ODF program transitions from its strong preclinical data into formal human studies will be another major focal point.

The immediate market reaction reflected some caution. In today's trading, BioNxt shares are down 3.13%, with the price at €0.37.

The coming period will be crucial for BioNxt. The company must work to formally finalize the LOI while simultaneously providing operational updates on the planned transition to human pharmacokinetic studies for its Cladribine formulation.